[Controlled study of iprazochrome effectiveness (Divascan) in prophylactic treatment of migraine].
The study was designed as double blind, placebo controlled. The patients were treated with 15 mg of iprazochrome daily in three equal doses for eight weeks, or--with equal amount of placebo tablets. The effectiveness was calculated with the use of Migraine Score (MS) by Couch et. al. 44 patients completed the study. In 21 the therapy was positive: 16 out of them were treated with iprazochrome, 5--with placebo. In 23 patients the treatment was negative: 19 out of them took placebo, 4--iprazochrome. Statistical analysis showed significant influence (chi 2 test: p < 0.001; Youle coeff. = 0.88). In iprazochrome group mean decrease of MS was significant after treatment (p < 0.01), but not significantly changed in the placebo group. According to our results iprazochrome was found effective in the prophylaxis of migraine.
Kozubski
W
W
Katedry i Kliniki Neurologii Akademii Medycznej w Poznaniu.
Prusiński
A
A
D000323:Adrenochrome / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000328:Adult; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D045563:Indolequinones; D008875:Middle Aged; D008881:Migraine Disorders / Q000517:prevention & control*; D012189:Retrospective Studies; D012702:Serotonin Antagonists / Q000627:therapeutic use*
D045563:Indolequinones; D012702:Serotonin Antagonists; D000323:Adrenochrome; C009742:iprazochrome